Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Friday, July 17th. Get Viking Therapeutics alerts:Get Our Latest Stock Analysis on VKTXViking Therapeutics Trading Up 0.2%NASDAQ:VKTX traded up $0.07 on Tuesday, hitting $34.51. Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last issued its earnings results on Wednesday, July 29th. Viking Therapeutics Company Profile(Get Free Report)Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Further ReadingReceive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.